Gaithersburg-based biotech MedImmune and the U.S Department of Commerce's National Institute of Standards and Technology, NIST, announced Friday a five-year joint agreement to research tools to develop new drugs or therapies, or make existing therapies more effective. The project is focused on biopharmaceuticals, drugs and treatments derived from biological, rather than chemical, sources.